ライフサイエンスコーパス: Richter

1 Richter and Koon successfully applied TEM analysis of co

2 Richter cyclization of o-(1,3-butadiynyl)phenyltriazene

3 Richter syndrome (RS) arising from chronic lymphocytic l

4 Richter syndrome (RS) derives from the rare transformati

5 Richter syndrome (RS) is associated with poor outcome.

6 Richter syndrome (RS) is defined as the transformation o

7 Richter syndrome (RS) occurs in up to 15% of patients wi

8 Richter syndrome (RS) of chronic lymphocytic leukemia (C

9 Richter syndrome (RS) represents the transformation of c

10 Richter transformation (RT) is a paradigmatic evolution

11 Richter transformation (RT) is defined as an aggressive

12 Richter transformation (RT) refers to the development of

13 Richter transformation is one of the most challenging B-

14 Richter transformation usually presents as an aggressive

15 Richter's syndrome (RS) and fludarabine-refractory chron

16 Richter's Transformation (RT) is a poorly understood and

17 Richter's transformation (RT) is a progression of chroni

18 Richter's transformation (RT) is an aggressive lymphoma

19 Richter's transformation appeared to occur early and CLL

20 Richter's transformation occurred in 9 patients and Hodg

21 Richter's transformation was missed in 1 patient who had

22 ) samples were available for 47 (excluding 1 Richter) acalabrutinib-treated and 30 (excluding 6 Richt

23 months (IQR 10.4-18.4), there were two (4%) Richter transformations, but no progressions and no deat

24 r) acalabrutinib-treated and 30 (excluding 6 Richter) ibrutinib-treated patients.

25 FLUx for phylogenetic analyses of aggressive Richter-transformed chronic lymphocytic leukaemia sample

26 e 3 or higher infections (30.8% v 30.0%) and Richter transformations (3.8% v 4.9%) were comparable be

27 e toxicity (51%), CLL progression (29%), and Richter transformation (RT) (8%).

28 sis, metastatic squamous cell carcinoma, and Richter's syndrome), none in the venetoclax-rituximab an

29 eq in novel chronic lymphocytic leukemia and Richter syndrome mouse models, we report the detection o

30 lymphoma, diffuse large B-cell lymphoma, and Richter's transformation.

31 , including early-stage multiple myeloma and Richter's syndrome arising from chronic lymphocytic leuk

32 L) to high-grade B-cell lymphoma is known as Richter syndrome (RS), a rare event with dismal prognosi

33 ic patient; however, in this issue of Blood, Richter and colleagues share provocative new data taking

34 ndori, Hatanaka, Yamazaki, Needleman, Brown, Richter, Lanyi, & Maeda, manuscript in preparation) of t

35 oder and elemental/isotopic fractionation by Richter.

36 warm in late 2003 at Lake Tahoe, California (Richter magnitude < 2.2; depth of 29 to 33 kilometers),

37 phocytic leukemia (CLL), and has been called Richter's syndrome with HD features.

38 or lymphocyte infusion in patients with CLL, Richter's, and low-grade and intermediate-grade lymphoma

39 In the external cohort, Richter's transformation occurred in 17% of the high-ris

40 rs or older and had histologically confirmed Richter transformation (diffuse large B-cell lymphoma [D

41 ed >=18 years) with histologically confirmed Richter transformation, an Eastern Cooperative Oncology

42 PET/CT can detect Richter's transformation of CLL to diffuse large B-cell

43 progressed early on ibrutinib often develop Richter transformation (RT) with a short survival of abo

44 oclax, 3 without treatment need, 2 developed Richter transformation, and 1 dropped out).

45 nt had CLL progression; 2 patients developed Richter transformation.

46 emaining patients, PET/CT correctly excluded Richter's transformation.

47 Excluding Richter transformation, 96 of 300 patients (32%) develop

48 Outcomes for Richter transformation (RT) are poor with current therap

49 ive disease and exhibit the highest risk for Richter transformation among all CLL.

50 All patients were screened for Richter's transformation and cases confirmed by biopsy w

51 ied subgroup analyses by line of therapy for Richter transformation and TP53 aberration and/or del(17

52 ults develop seismicity that has a Gutenberg-Richter distribution, this is only a transient state tha

53 like the self-similar (power law) Gutenberg-Richter frequency-size statistics.

54 cs, magnitude correlations and low Gutenberg-Richter b-values.

55 s are higher, accompanied by lower Gutenberg-Richter b-values.

56 ies of the seismicity, such as the Gutenberg-Richter (G-R) distribution.

57 model very naturally explains the Gutenberg-Richter law.

58 obey a power law analogous to the Gutenberg-Richter relation, and the long-term release of geodetic

59 is the rupture area, and obey the Gutenberg-Richter relationship between frequency and magnitude.

60 show small event complexity of the Gutenberg-Richter type.

61 The law links together the Gutenberg--Richter Law, the Omori Law of aftershocks, and the fract

62 ; this result is analogous to the Gutenberg--Richter power law describing the histogram of earthquake

63 ting the TLR pathway in murine CLL and human Richter syndrome (RS) patient-derived xenograft (PDX) ce

64 an indolent to a high-grade malignancy (ie, Richter syndrome [RS]) and treatment, with a focus on ne

65 As we found loss of BAX in Richter's syndrome patients after venetoclax failure, we

66 N2A, CDKN2B, and TP53 frequently co-occur in Richter syndrome (RS), and BCR stimulation of human RS c

67 ients with intermediate-grade lymphoma or in Richter's transformation received cisplatin 25 mg/m2 dai

68 Disease progression includes Richter's transformation (RT) or progressive CLL.

69 Secondary malignancies including Richter's transformation occurred in 13.1% in the FCR gr

70 on invariably primes CLL transformation into Richter syndrome.

71 fludarabine and harboring complex karyotype, Richter transformation presents a distinct and challengi

72 , Bernert JT, Blount BC, Sosnoff CS, Wang L, Richter P, Pirkle JL.

73 L arising from chronic lymphocytic leukemia (Richter transformation; n = 7), Waldenstrom macroglobuli

74 patients with chronic lymphocytic leukemia, Richter transformation (RT) reflects the development of

75 patients received epcoritamab as first-line Richter transformation-directed therapy.

76 ously treated diffuse large B-cell lymphoma (Richter transformation) or prolymphocytic leukaemia tran

77 sformation to diffuse large B-cell lymphoma, Richter syndrome (RS), which is associated with a poor p

78 es, including diffuse large B-cell lymphoma, Richter's transformation, mantle cell lymphoma, follicul

79 events during and subsequent to the 4 major (Richter Scale >6.0) Canterbury earthquakes during the ye

80 Unlike many other hematologic malignancies, Richter syndrome (RS), an aggressive B cell lymphoma ori

81 L cells and the H-RS cells in three cases of Richter's syndrome with HD features by using a single ce

82 the same clonal population in some cases of Richter's syndrome with HD features.

83 No cases of Richter's transformation (CLL that has evolved into larg

84 the accuracy of PET/CT for the diagnosis of Richter's transformation of chronic lymphocytic leukemia

85 For the specific diagnosis of Richter's transformation of CLL to diffuse large B-cell

86 atus of 0-2, and up to two previous lines of Richter transformation-directed therapy.

87 roliferation and reveal a novel mechanism of Richter transformation.

88 g characteristics, and treatment outcomes of Richter's syndrome (RS) and factors predicting response

89 r treatment-free survival and higher risk of Richter transformation.

90 ubset 8 CLL, notable for the highest risk of Richter's transformation among all CLLs and provide addi

91 than 5 were considered highly suggestive of Richter's transformation.

92 use large B-cell lymphoma (DLBCL) variant of Richter transformation (DLBCL-RT) is typically chemoresi

93 s with chronic lymphocytic leukemia (CLL) or Richter syndrome (RS) over a 10-year period at a referra

94 h-risk chronic lymphocytic leukemia (CLL) or Richter's transformation (RT).

95 therapy for chronic lymphocytic leukaemia or Richter transformation.

96 lymphoma (SLL), prolymphocytic leukemia, or Richter's transformation who failed >/=2 prior therapies

97 ormation of CLL into aggressive lymphoma, or Richter syndrome (RS), has remained incompletely charact

98 four of 14 fatal cases of CLL progression or Richter transformation in the placebo group.

99 f 82 patients received at least one previous Richter transformation-directed therapy.

100 ansformation, most of whom received previous Richter transformation-directed therapy, including coval

101 ion for patients with relapsed or refractory Richter transformation after treatment with a covalent B

102 onic spectroscopy with sub-10 fs resolution, Richter and Branchi et al. extract carrier thermalizatio

103 Since Richter's description in the literature in 1989 of the f

104 spite such advances, cell-escape strategies, Richter transformation, and immunosuppression remain as

105 We analysed data from the Richter transformation cohort of a larger, ongoing, phas

106 mplete remission, and 1 had remission of the Richter's transformation component but had persistent CL

107 ggressive form of B cell lymphoma over time (Richter s syndrome) and show a significantly worse treat

108 c leukaemia or small lymphocytic lymphoma to Richter transformation was 7.6 years (range 0-23.9).

109 ymph node involvement, and predisposition to Richter syndrome transformation.

110 hronic lymphocytic leukaemia who progress to Richter transformation (diffuse large B-cell lymphoma mo

111 frequency during disease progression toward Richter transformation (31.0%), as well as in chemorefra

112 ia, three chronic lymphocytic leukaemia, two Richter's syndrome, two sepsis, and one each of acute my

113 owed similar patterns with U-CLLs undergoing Richter transformation.

114 ds are good candidates for the classical von Richter reaction.

115 nitro groups in a manner similar to the von Richter reaction to the nitroso intermediates, to initia

116 ) patients manifested PD on therapy: 17 with Richter transformation (RT) and 8 with progressive CLL/S

117 4 with mantle cell leukemia/lymphoma, 2 with Richter transformation).

118 neutropenia (p=0.031) and all patients with Richter transformation (RT; n=11) had CH (p=0.004).

119 b monotherapy in a subgroup of patients with Richter transformation from the multicentre, open-label,

120 combination-based regimens for patients with Richter transformation is warranted.

121 , 2014, and April 25, 2016, 25 patients with Richter transformation were enrolled; 12 (48%) were male

122 In patients with Richter transformation, epcoritamab monotherapy showed c

123 sing safety and activity among patients with Richter transformation, most of whom received previous R

124 potential treatment option for patients with Richter transformation.

125 3xCD20 bispecific antibody, in patients with Richter transformation.

126 atively poor in this cohort of patients with Richter transformation.

127 March 21, 2025, we enrolled 42 patients with Richter transformation.

128 Patients with Richter's syndrome (RS) have a poor prognosis with conve

129 The clinical response in patients with Richter's transformation was promising and supports furt

130 In 10 (91%) of 11 patients with Richter's transformation, PET/CT detected sites of abnor

131 lymphoma to seven (35%) of 20 patients with Richter's transformation.

132 l lymphoma, and 13 (65%) of 20 patients with Richter's transformation.